News

Zymenex in Phase 3 clinical trial in patients with the rare disease alpha-Mannosidosis
Chiesi Group to acquire Zymenex
Zymenex in Phase 3 clinical trial in patients with the rare disease alpha-Mannosidosis
Zymenex enzyme moves into Phase 2b clinical trials in patients with the rare disease alpha-Mannosidosis
Zymenex enzyme gets US Orphan Drug Designation Approval from FDA
Positive clinical effect in Phase 2 trial in patients with the rare disease alpha-Mannosidosis
Zymenex enzyme gets EU Orphan Drug Designation Approval
Zymenex enzyme in Phase 2 clinical trials in patients with the rare disease alpha-Mannosidosis
Zymenex enzyme gets EU-millions for clinical trials in ALPHA-MAN project
Zymenex receives 500.000 dkr from the Advisory Council on Technology for a collaborative technology with Danish Technological Institute
Page 1 of 4
Zymenex A/S Roskildevej 12 C
3400 Hillerød, DK
Tel  +45 48250054
Fax  +45 48251054
Affiliate Sweden Agavägen 58
181 55 Lidingö, S
Tel  +46 8 7670203
Fax  +46 8 7670233

© 2004 Zymenex A/S